FGL(L)

A 15-amino acid synthetic peptide derived from the second fibronectin type III module of neural cell adhesion molecule (NCAM). FGL(L) mimics the interaction between NCAM and the fibroblast growth factor receptor 1 (FGFR1), promoting neurite outgrowth, synaptic plasticity, and neuroprotection. It was developed as a drug-like NCAM mimetic for cognitive enhancement and neurodegenerative disease research.

• Binds and activates FGFR1, triggering downstream MAPK/ERK and PLCgamma signaling cascades
• Mimics the NCAM-FGFR1 interaction that is critical for synaptic plasticity and memory consolidation
• Promotes presynaptic and postsynaptic structural remodeling
• Reduces microglial activation and neuroinflammation through FGFR1-mediated anti-inflammatory signaling

• Active CNS malignancy (FGFR1 involvement in certain tumors)
• Pregnancy or breastfeeding
• No established human dosing guidelines — research use only

Store at 2–8°C (36–46°F) for up to 3 months. For long-term storage, keep at -20°C (-4°F). Once reconstituted, refrigerate and use within 14 days.

FGL(L) was developed by researchers at the University of Copenhagen and ENKAM Pharmaceuticals. Published studies in the Journal of Neuroscience and Neurobiology of Disease demonstrated that subcutaneous FGL administration improved spatial memory in rats and enhanced LTP in hippocampal slices. A Phase I clinical trial in healthy elderly volunteers was conducted, establishing preliminary safety and tolerability. Preclinical Alzheimer's models showed FGL reduced amyloid-beta-induced neuronal death and rescued cognitive deficits. The NCAM-mimetic approach represents a unique mechanism for cognitive enhancement distinct from neurotransmitter-based strategies.